| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-06-0391 |
| P698 | PubMed publication ID | 17041086 |
| P2093 | author name string | Beverly A Teicher | |
| P433 | issue | 10 | |
| P304 | page(s) | 2435-2443 | |
| P577 | publication date | 2006-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Tumor models for efficacy determination | |
| P478 | volume | 5 |
| Q36072561 | A microphysiological system model of therapy for liver micrometastases |
| Q33707844 | A novel orthotopic mouse model of human anaplastic thyroid carcinoma |
| Q33615020 | An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse |
| Q34250295 | An improved syngeneic orthotopic murine model of human breast cancer progression |
| Q90043616 | Animal Models to Study Cancer and Its Microenvironment |
| Q35720139 | Animal models and molecular imaging tools to investigate lymph node metastases |
| Q36093956 | Animal models for exploring the pharmacokinetics of breast cancer therapies |
| Q37002288 | Antitumor efficacy testing in rodents |
| Q38904840 | Application of a fluorescence resonance energy transfer (FRET)-based biosensor for detection of drug-induced apoptosis in a 3D breast tumor model |
| Q34055939 | Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells |
| Q39365692 | Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor |
| Q48242134 | Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography |
| Q88566946 | Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology |
| Q41872259 | Confidence intervals for the difference of median failure times applied to censored tumor growth delay data |
| Q39122818 | Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells |
| Q36887663 | Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma |
| Q39048792 | Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer |
| Q37286152 | Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. |
| Q50047549 | Effects of low-intensity ultrasound combined with low-dose carboplatin in an orthotopic hamster model of tongue cancer: A preclinical study |
| Q26783746 | Emerging Applications for Optically Enabled Intravital Microscopic Imaging in Radiobiology |
| Q35974087 | Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines |
| Q33684453 | Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer |
| Q64108509 | Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX) |
| Q35110920 | First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma |
| Q35170403 | Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis |
| Q34334533 | In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy |
| Q42370589 | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| Q92027154 | Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization |
| Q39475114 | Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma |
| Q38734048 | Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme |
| Q40823356 | Institutional Animal Care and Use Committee Considerations Regarding the Use of Virus-Induced Carcinogenesis and Oncolytic Viral Models |
| Q37127936 | Is tail vein injection a relevant breast cancer lung metastasis model? |
| Q38889829 | Liver metastases: Microenvironments and ex-vivo models. |
| Q38013289 | Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development |
| Q36770262 | Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. |
| Q28076041 | Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer |
| Q64244399 | Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches |
| Q30579390 | NaGdF4 Nanoparticle-Based Molecular Probes for Magnetic Resonance Imaging of Intraperitoneal Tumor Xenografts in Vivo |
| Q54478528 | PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. |
| Q33720164 | Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. |
| Q38240079 | Pre-clinical research in small animals using radiotherapy technology--a bidirectional translational approach |
| Q35996689 | Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents: TABLE 1 |
| Q28075903 | Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents |
| Q54565907 | Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. |
| Q37816960 | Preclinical development of molecular-targeted agents for cancer |
| Q42909125 | Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor |
| Q40433016 | Preclinical evaluation of radiation and systemic, RGD-targeted, adeno-associated virus phage-TNF gene therapy in a mouse model of spontaneously metastatic melanoma |
| Q27322080 | Preclinical mouse cancer models: a maze of opportunities and challenges |
| Q37311933 | Preclinical screening methods in cancer |
| Q35179487 | Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin |
| Q35782471 | Quantitative volumetric imaging of normal, neoplastic and hyperplastic mouse prostate using ultrasound |
| Q38674749 | Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip |
| Q36062154 | Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels |
| Q39313933 | Resveratrol Exerts Differential Effects in Vitro and in Vivo against Ovarian Cancer Cells |
| Q39887554 | Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model |
| Q39894607 | Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling |
| Q34613544 | Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip |
| Q37706665 | Sinomenine hydrochloride inhibits breast cancer metastasis by attenuating inflammation-related epithelial-mesenchymal transition and cancer stemness |
| Q36828773 | Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo. |
| Q34687026 | Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system |
| Q44456046 | The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy |
| Q38919020 | The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy |
| Q26744837 | The Smart Drug Delivery System and Its Clinical Potential |
| Q37567174 | The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma |
| Q38082176 | Towards more effective advanced drug delivery systems1 |
| Q36910546 | Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib |
| Q38707936 | Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside |
| Q37732720 | Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua |
| Q39020856 | Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. |
| Q30417587 | Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model |
Search more.